Literature DB >> 29501990

Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.

Mark J Niciu1, Bridget J Shovestul1, Brittany A Jaso2, Cristan Farmer1, David A Luckenbaugh3, Nancy E Brutsche1, Lawrence T Park1, Elizabeth D Ballard1, Carlos A Zarate4.   

Abstract

BACKGROUND: Ketamine induces rapid and robust antidepressant effects, and many patients also describe dissociation, which is associated with antidepressant response. This follow-up study investigated whether antidepressant efficacy is uniquely related to dissociative symptom clusters.
METHODS: Treatment-resistant patients with major depressive disorder (MDD) or bipolar disorder (BD) (n = 126) drawn from three studies received a single subanesthetic (0.5 mg/kg) ketamine infusion. Dissociative effects were measured using the Clinician-Administered Dissociative States Scale (CADSS). Antidepressant response was measured using the 17-item Hamilton Depression Rating Scale (HAM-D). A confirmatory factor analysis established the validity of CADSS subscales (derealization, depersonalization, amnesia), and a general linear model with repeated measures was fitted to test whether subscale scores were associated with antidepressant response.
RESULTS: Factor validity was supported, with a root mean square error of approximation of .06, a comparative fit index of .97, and a Tucker-Lewis index of .96. Across all studies and timepoints, the depersonalization subscale was positively related to HAM-D percent change. A significant effect of derealization on HAM-D percent change was observed at one timepoint (Day 7) in one study. The amnesia subscale was unrelated to HAM-D percent change. LIMITATIONS: Possible inadequate blinding; combined MDD/BD datasets might have underrepresented ketamine's antidepressant efficacy; the possibility of Type I errors in secondary analyses.
CONCLUSIONS: From a psychometric perspective, researchers may elect to administer only the CADSS depersonalization subscale, given that it was most closely related to antidepressant response. From a neurobiological perspective, mechanistic similarities may exist between ketamine-induced depersonalization and antidepressant response, although off-target effects cannot be excluded. Published by Elsevier B.V.

Entities:  

Keywords:  Depression; Dissociation; Ketamine

Mesh:

Substances:

Year:  2018        PMID: 29501990      PMCID: PMC5858990          DOI: 10.1016/j.jad.2018.02.049

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  29 in total

Review 1.  Mechanisms of blockade of excitatory amino acid receptor channels.

Authors:  J F MacDonald; L M Nowak
Journal:  Trends Pharmacol Sci       Date:  1990-04       Impact factor: 14.819

2.  Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.

Authors:  Peter Sos; Monika Klirova; Tomas Novak; Barbora Kohutova; Jiri Horacek; Tomas Palenicek
Journal:  Neuro Endocrinol Lett       Date:  2013       Impact factor: 0.765

3.  Dissociation in Psychiatric Disorders: A Meta-Analysis of Studies Using the Dissociative Experiences Scale.

Authors:  Lisa Lyssenko; Christian Schmahl; Laura Bockhacker; Ruben Vonderlin; Martin Bohus; Nikolaus Kleindienst
Journal:  Am J Psychiatry       Date:  2017-09-26       Impact factor: 18.112

4.  Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

Authors:  Carlos A Zarate; Nancy E Brutsche; Lobna Ibrahim; Jose Franco-Chaves; Nancy Diazgranados; Anibal Cravchik; Jessica Selter; Craig A Marquardt; Victoria Liberty; David A Luckenbaugh
Journal:  Biol Psychiatry       Date:  2012-01-31       Impact factor: 13.382

5.  Do the dissociative side effects of ketamine mediate its antidepressant effects?

Authors:  David A Luckenbaugh; Mark J Niciu; Dawn F Ionescu; Neal M Nolan; Erica M Richards; Nancy E Brutsche; Sara Guevara; Carlos A Zarate
Journal:  J Affect Disord       Date:  2014-02-18       Impact factor: 4.839

6.  Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale.

Authors:  Gerrit I van Schalkwyk; Samuel T Wilkinson; Larry Davidson; Wendy K Silverman; Gerard Sanacora
Journal:  J Affect Disord       Date:  2017-09-28       Impact factor: 4.839

7.  Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

Authors:  B Moghaddam; B Adams; A Verma; D Daly
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

8.  Preliminary differences in resting state MEG functional connectivity pre- and post-ketamine in major depressive disorder.

Authors:  Allison C Nugent; Stephen E Robinson; Richard Coppola; Carlos A Zarate
Journal:  Psychiatry Res Neuroimaging       Date:  2016-06-23       Impact factor: 2.376

Review 9.  A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.

Authors:  A McGirr; M T Berlim; D J Bond; M P Fleck; L N Yatham; R W Lam
Journal:  Psychol Med       Date:  2014-07-10       Impact factor: 7.723

Review 10.  The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects.

Authors:  Sungho Maeng; Carlos A Zarate
Journal:  Curr Psychiatry Rep       Date:  2007-12       Impact factor: 8.081

View more
  19 in total

1.  Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways.

Authors:  Ji-Woon Kim; Lisa M Monteggia
Journal:  Behav Brain Res       Date:  2019-11-21       Impact factor: 3.332

Review 2.  Ketamine: Leading us into the future for development of antidepressants.

Authors:  Flavia R Carreno; Daniel J Lodge; Alan Frazer
Journal:  Behav Brain Res       Date:  2020-02-02       Impact factor: 3.332

3.  Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.

Authors:  Danilo De Gregorio; Argel Aguilar-Valles; Katrin H Preller; Boris Dov Heifets; Meghan Hibicke; Jennifer Mitchell; Gabriella Gobbi
Journal:  J Neurosci       Date:  2020-11-30       Impact factor: 6.167

Review 4.  Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress.

Authors:  Michael D Kritzer; Nicholas A Mischel; Jonathan R Young; Christopher S Lai; Prakash S Masand; Steven T Szabo; Sanjay J Mathew
Journal:  Ann Clin Psychiatry       Date:  2022-02       Impact factor: 2.691

5.  Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression.

Authors:  Elia E Acevedo-Diaz; Grace W Cavanaugh; Dede Greenstein; Christoph Kraus; Bashkim Kadriu; Lawrence Park; Carlos A Zarate
Journal:  J Psychiatr Res       Date:  2020-07-30       Impact factor: 4.791

Review 6.  Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action.

Authors:  Madison N Irwin; Amy VandenBerg
Journal:  Ment Health Clin       Date:  2021-05-12

7.  Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report.

Authors:  Júlia Vendrell-Serres; Óscar Soto-Angona; Amanda Rodríguez-Urrutia; Gara Arteaga-Henríquez; Josep A Ramos-Quiroga
Journal:  Ther Adv Psychopharmacol       Date:  2021-06-16

8.  Rewarding Subjective Effects of the NMDAR Antagonist Nitrous Oxide (Laughing Gas) Are Moderated by Impulsivity and Depressive Symptoms in Healthy Volunteers.

Authors:  Sunjeev K Kamboj; Hannah Zhao; Luzia Troebinger; Giulia Piazza; Emma Cawley; Vanessa Hennessy; Georges Iskandar; Ravi K Das
Journal:  Int J Neuropsychopharmacol       Date:  2021-07-23       Impact factor: 5.176

9.  Clinical trials for rapid changes in suicidal ideation: Lessons from ketamine.

Authors:  Elizabeth D Ballard; Jessica Fields; Cristan A Farmer; Carlos A Zarate
Journal:  Suicide Life Threat Behav       Date:  2021-02

10.  Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression.

Authors:  Adam Włodarczyk; Wiesław J Cubała; Maria Gałuszko-Węgielnik; Joanna Szarmach
Journal:  Ther Adv Psychopharmacol       Date:  2021-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.